Impact of minimal tumor burden on antibody response to vaccination.
Four randomized phase III trials conducted recently in melanoma patients in the adjuvant setting have been based in part on the correlation between antibody responses in immunized patients and improved survival. Each of these randomized trials demonstrated no clinical benefit, although again there was a significant correlation between antibody response after vaccination and disease free and overall survival. To better understand this paradox, we established a surgical adjuvant model targeting GD2 ganglioside on EL4 lymphoma cells injected into the foot pad followed by amputation at variable intervals. Our findings are (1) comparable strong therapeutic benefit resulted from treatment of mice after amputation with a GD2-KLH conjugate vaccine or with anti-GD2 monoclonal antibody 3F8. (2) The strongest correlation was between antibody induction in response to vaccination and prolonged survival. (3) Antibody titers in response to vaccination in tumor challenged mice as compared to unchallenged mice were far lower despite the absence of detectable recurrences at the time. (4) The half life of administered 3F8 monoclonal antibody (but not control antibody) in challenged mice administered was significantly shorter than the half life of 3F8 antibody in unchallenged controls. The correlation between vaccine-induced antibody titers and prolonged survival may reflect, at least in part, increased tumor burden in antibody-negative mice. Absorption of vaccine-induced antibodies by increased, although not detected tumor burden may also explain the correlation between vaccine-induced antibody titers and survival in the adjuvant clinical trials described above.
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Soo-Kie
SK
Kim
Xiaohong
X
Wu
Govind
G
Ragupathi
John
J
Gathuru
Fusataka
F
Koide
Nai-Kong
NK
Cheung
Katherine
K
Panageas
Philip O
PO
Livingston
D000276:Adjuvants, Immunologic; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000096:biosynthesis*; D000920:Antibody-Dependent Cell Cytotoxicity; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005732:Gangliosides / Q000276:immunology*; D006433:Hemocyanins / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology* / Q000627:therapeutic use; D008223:Lymphoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D047368:Tumor Burden; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
C419226:3F8 antibody; D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D005732:Gangliosides; D007074:Immunoglobulin G; D018074:Vaccines, Conjugate; C019403:ganglioside, GD2; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin
Clin Cancer Res. 2003 Nov 1;9(14):5214-20
14614001
J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):59-68
8859725
Cancer Res. 1994 Jan 1;54(1):197-203
8261439
Cancer Res. 2005 Nov 15;65(22):10562-8
16288049
J Clin Oncol. 2013 Oct 20;31(30):3831-7
24019551
Cancer Res. 1998 Jul 1;58(13):2844-9
9661900
Lancet. 1994 May 14;343(8907):1177-83
7909866
Cancer Res. 1987 Jun 1;47(11):2771-6
3494504
Cancer Res. 2005 Apr 15;65(8):3410-8
15833876
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
Cancer Res. 1959 Sep;19:824-30
13851274
Ann Surg. 1992 Oct;216(4):463-82
1417196
Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629-33
6296843
J Immunol. 1991 Jan 15;146(2):431-7
1987271
Vaccine. 1999 Nov 12;18(7-8):597-603
10547417
J Natl Cancer Inst. 1993 Dec 15;85(24):2012-8
8246287
J Exp Med. 1995 Nov 1;182(5):1609-14
7595233
J Neurochem. 1963 Sep;10:613-23
14066623
Clin Cancer Res. 1995 Jul;1(7):705-13
9816036
Int J Cancer. 1997 Sep 26;73(1):42-9
9334808
Cancer Res. 1985 Jun;45(6):2642-9
2580625
J Natl Cancer Inst. 1981 Feb;66(2):249-54
6935475
Vaccine. 2000 Oct 15;19(4-5):530-7
11027818
Biochim Biophys Acta. 1994 Apr 12;1226(1):105-9
7908833
J Exp Med. 1995 Jul 1;182(1):67-74
7540657
Melanoma Res. 1997 Aug;7 Suppl 2:S155-62
9578432
J Clin Oncol. 2009 Jan 1;27(1):38-44
19047287
J Clin Oncol. 2001 Nov 15;19(22):4189-94
11709561
Cancer Immunol Immunother. 1991;34(1):63-9
1662114
Cancer Res. 2006 Nov 1;66(21):10567-75
17079481
Vaccine. 2007 Sep 27;25 Suppl 2:B4-16
17646038
Clin Cancer Res. 2004 Mar 1;10(5):1670-7
15014018
Cancer Res. 1989 Jun 1;49(11):2857-61
2720646
Cancer Immunol Immunother. 2007 Sep;56(9):1443-58
17597331
Cancer. 1995 Jan 15;75(2):495-502
7812920